Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

AUP 16

Next Previous
Drug Profile

AUP 16

Alternative Names: AUP-16; AUP1602-C

Latest Information Update: 09 Jan 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Aurealis Pharma
  • Developer Aurealis Therapeutics
  • Class Anti-inflammatories; Bacteria; Probiotics
  • Mechanism of Action Bacteria replacements; Colony stimulating factor stimulants; Fibroblast growth factor stimulants; Interleukin 4 stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Diabetic foot ulcer
  • Phase I Varicose ulcer
  • Preclinical Pressure ulcer

Most Recent Events

  • 28 Oct 2024 Aurealis Therapeutics completes enrolment in the DIAMEND phase II trial for Diabetic foot ulcer in Italy, Germany, and Poland (Topical)
  • 11 Mar 2024 AUP 16 receives Priority Medicine (PRIME) status for Diabetic foot ulcer in Europe
  • 21 Jul 2023 Phase-II clinical trials in Diabetic foot ulcer in Poland, Italy, and Germany (Topical)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top